Bacterial Translocation as Inflammatory Driver in Crohn's Disease
- PMID: 34557484
- PMCID: PMC8452966
- DOI: 10.3389/fcell.2021.703310
Bacterial Translocation as Inflammatory Driver in Crohn's Disease
Abstract
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract responsible for intestinal lesions. The multifactorial etiology attributed to CD includes a combination of environmental and host susceptibility factors, which result in an impaired host-microbe gut interaction. Bacterial overgrowth and dysbiosis, increased intestinal barrier permeability, and altered inflammatory responses in patients with CD have been described in the past. Those events explain the pathogenesis of luminal translocation of bacteria or its products into the blood, a frequent event in CD, which, in turn, favors a sustained inflammatory response in these patients. In this review, we navigate through the interaction between bacterial antigen translocation, permeability of the intestinal barrier, immunologic response of the host, and genetic predisposition as a combined effect on the inflammatory response observed in CD. Several lines of evidence support that translocation of bacterial products leads to uncontrolled inflammation in CD patients, and as a matter of fact, the presence of gut bacterial genomic fragments at a systemic level constitutes a marker for increased risk of relapse among CD patients. Also, the significant percentage of CD patients who lose response to biologic therapies may be influenced by the translocation of bacterial products, which are well-known drivers of proinflammatory cytokine production by host immune cells. Further mechanistic studies evaluating cellular and humoral immune responses, gut microbiota alterations, and genetic predisposition will help clinicians to better control and personalize the management of CD patients in the future.
Keywords: Crohn’s disease; NOD2; anti-TNF-α; bacterial translocation; dysbiosis; inflammatory response; intestinal permeability.
Copyright © 2021 Linares, Francés, Gutiérrez and Juanola.
Conflict of interest statement
AG has served as speaker, consultant, or advisory member for, or received research funding from MSD, ABBVIE, TAKEDA, KERN PHARMA, PFIZER, OTSUKA, SHIRE, and JANSSEN, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Aden K., Rehman A., Waschina S., Pan W. H., Walker A., Lucio M., et al. (2019). Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Gastroenterology 157 1279–1292.e11. - PubMed
-
- Ainsworth M. A., Bendtzen K., Brynskov J. (2008). Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am. J. Gastroenterol. 103 944–948. 10.1111/j.1572-0241.2007.01638.x - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
